2 Greenwich Office Park
Suite 210
Greenwich, CT 06831
203 863-0003
77 Lafayette Place
Suite 302
Greenwich, CT 06830
203 863-0003
21 Reade Place
Suite 2100
Poughkeepsie, NY 12601
203 863-0003
© 2024 The Plastic & Reconstructive Surgery Group - All Rights Reserved - Featured Realself Breast Reconstruction Expert - Terms of Use - Sitemap
News
Tamoxifen Plus Radiation With DCIS Lumpectomy Lowers Cancer Recurrence Risk
Posted Date: March 16, 2011
For women with ductal carcinoma in situ (DCIS), adding radiation therapy and/or tamoxifen to treatment lowers the risk of the recurrence of aggressive cancer, doctors at Allegheny General Hospital and the National Surgical Adjuvant Breast Bowel Project revealed in the Journal of the National Cancer Institute.
For women with ductal carcinoma in situ (DCIS), adding radiation therapy and/or tamoxifen to treatment lowers the risk of the recurrence of aggressive cancer, doctors at Allegheny General Hospital and the National Surgical Adjuvant Breast Bowel Project revealed in the Journal of the National Cancer Institute.
Female participants with DCIS were followed for between 13.5 to 17 years in two previous NSABP trials. Breast tumor recurrence in the previously affected breast went down 52% in those who received a lumpectomy combined with radiotherapy, compared to those who only had the surgery. When tamoxifen was also added to the treatment of patients with estrogen receptor positive DCIS, breast tumor recurrence in the previously affected breast risk fell 32% compared to those who had a lumpectomy and radiotherapy only.
>> Read more: Journal of the National Cancer Institute